Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 3Breast Neoplasms 3Smoldering Multiple Myeloma 1Psoriasis 1Polycystic Ovary Syndrome 1Osteoarthritis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Liver Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Autoimmune Diseases 1Arthritis, Rheumatoid 1

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Docosahexaenoic Acids × 1 year × Clear all
NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Affiliated Hospital of Guangdong Medical University

Phase 2 Not yet recruiting
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡